Ashton Thomas Private Wealth LLC Buys Shares of 37 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Ashton Thomas Private Wealth LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 37 shares of the biopharmaceutical company’s stock, valued at approximately $39,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Stephens Consulting LLC acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at about $26,000. West Paces Advisors Inc. raised its stake in shares of Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 23 shares during the period. Crewe Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $28,000. Lynx Investment Advisory purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $33,000. Finally, Family Firm Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $33,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

REGN has been the topic of several recent research reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. Guggenheim raised their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Piper Sandler raised their target price on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a research note on Friday, August 23rd. JPMorgan Chase & Co. raised their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Finally, Argus raised their target price on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,109.70.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $1,153.08 on Tuesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $769.19 and a twelve month high of $1,211.20. The company has a market capitalization of $127.05 billion, a P/E ratio of 34.06, a price-to-earnings-growth ratio of 3.97 and a beta of 0.12. The firm has a 50-day moving average price of $1,126.24 and a two-hundred day moving average price of $1,027.77. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. During the same period last year, the company earned $8.79 EPS. The firm’s revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,137 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the sale, the executive vice president now directly owns 12,931 shares of the company’s stock, valued at approximately $13,540,179.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the sale, the director now directly owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Marion Mccourt sold 1,137 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the completion of the sale, the executive vice president now directly owns 12,931 shares in the company, valued at $13,540,179.41. The disclosure for this sale can be found here. Insiders have sold 10,026 shares of company stock valued at $11,498,705 in the last ninety days. Insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.